Pain during IUD insertion is one of the most commonly cited barriers to long-acting reversible contraception uptake — and a problem that has lacked a well-evidenced clinical solution. This meta-analysis offers meaningful, if preliminary, clarity: delivering anesthetic directly into the uterine cavity appears to reduce procedural pain, but the benefit is highly agent-dependent.
Pooling six randomized controlled trials involving 651 women — 68% of whom were nulliparous, the group typically most vulnerable to procedural pain — researchers found that intrauterine anesthesia (IUA) produced a statistically significant reduction in pain during IUD insertion compared to saline placebo (standardized mean difference –0.47; 95% CI –0.90 to –0.03). Critically, subgroup analysis revealed that this benefit was driven almost entirely by lidocaine: two trials encompassing 262 patients showed highly significant pain reduction with intrauterine lidocaine (p = 0.0002), while two trials using other anesthetic agents in 165 patients showed no significant effect (p = 0.27). Post-insertion pain did not differ meaningfully between IUA and placebo groups.
Several important caveats constrain interpretation. The meta-analysis rests on just six trials with 651 participants — a modest evidence base for clinical protocol changes. Heterogeneity was moderate (I² = 58%), suggesting meaningful variation across study populations, insertion techniques, or lidocaine concentrations that pooled estimates cannot fully resolve. The effect size itself, while statistically significant, falls in the small-to-moderate range, and the confidence interval barely excludes zero — a reminder that the true effect could be closer to negligible than the point estimate implies. Post-insertion analgesia showed no benefit, which limits the case for IUA as a comprehensive pain management strategy.
Within the broader contraceptive care landscape, this finding is incremental rather than paradigm-shifting, but it carries real clinical weight. Procedural pain has measurable effects on IUD discontinuation and uptake. If intrauterine lidocaine can be standardized as a low-risk adjunct — it is already used in related gynecological procedures — even modest pain reduction at the moment of insertion may translate to population-level improvements in contraceptive access and continuation.